• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

    8/3/22 4:01:00 PM ET
    $MRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRTX alert in real time by email

    SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates.

    "Mirati continues to advance the development of a broad portfolio of targeted oncology medicines," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "We are progressing toward the potential launch of adagrasib for patients with previously treated non-small cell lung cancer harboring a KRASG12C mutation in the U.S. this year. In addition, we have submitted a Marketing Authorization Application to the European Medicines Agency, bringing us one step closer to expanding the potential availability of adagrasib in the European Union. We continue to progress our sitravatinib and MRTX0902 clinical programs, which strengthen our targeted oncology portfolio. Our financial position remains strong, enabling continued investment and advancement of our extensive oncology pipeline."

    Pipeline Updates

    Adagrasib (Potent and selective KRASG12C inhibitor)

    • Presented full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with previously treated non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These results were published concurrently in the New England Journal of Medicine. (View Release)

    • Presented late-breaking data on adagrasib in patients with KRASG12C-mutated NSCLC with active and untreated central nervous system (CNS) metastases at the 2022 ASCO Annual Meeting. (View Release)
    • Submitted a Marketing Authorization Application to the European Medicines Agency for adagrasib for the treatment of patients with previously treated NSCLC harboring a KRASG12C mutation. (View Release)

    Sitravatinib (Potent TAM receptor inhibitor)

    • Anticipated to achieve the number of events needed to trigger an interim analysis of overall survival in the global, registrational Phase 3 SAPPHIRE study evaluating sitravatinib plus nivolumab (OPDIVO®)1 in second or third line non-squamous NSCLC in the fourth quarter of 2022.

    MRTX0902 (Potent SOS1 inhibitor)

    • Submitted an Investigational New Drug (IND) application to the U.S. FDA to evaluate MRTX0902, a selective SOS1 inhibitor, which shifts KRAS into its inactivated state resulting in significantly increased activity of adagrasib and other KRAS inhibitors in preclinical models and may improve clinical efficacy of adagrasib in patients with KRAS G12C mutations. The Company expects to initiate a Phase 1/2 clinical study by year-end 2022.

    Recent Corporate Updates

    • Announced the appointment of Laurie Stelzer as Chief Financial Officer. (View Release)

    Second Quarter 2022 Financial Results

    • Cash, cash equivalents, and short-term investments of approximately $1.2 billion as of June 30, 2022
    • Research and development expenses for the second quarter 2022 were $128.3 million, compared to $134.6 million for the same period in 2021. The decrease was primarily related to a decrease in manufacturing costs that occurred after our 2021 NDA filing for the adagrasib program, offset by increases in headcount-related costs, including share-based compensation, due to increased headcount associated with the growth of our portfolio. Research and development expenses for the six months ended June 30, 2022 were $259.3 million, compared to $238.6 million for the same period in 2021. The increase was primarily related to increases in headcount-related costs, including share-based compensation, due to increased headcount associated with the growth of our portfolio, offset by a decrease in manufacturing costs that occurred after our 2021 NDA filing for the adagrasib program. The Company recognized research and development-related share-based compensation expenses of $22.8 million during the second quarter of 2022, compared to $16.5 million for the same period in 2021, and $49.1 million during the six months ended June 30, 2022, compared to $31.0 million for the same period in 2021.
    • General and administrative expenses for the second quarter of 2022 were $54.2 million, compared to $29.6 million for the same period in 2021. General and administrative expenses for the six months ended June 30, 2022 were $108.2 million, compared to $58.0 million for the same period in 2021. The increases were primarily due to an increase in commercial readiness costs, including increases in headcount-related costs, as we prepare for a potential product launch. The Company recognized general and administrative-related share-based compensation expenses of $15.9 million in the second quarter of 2022, compared to $11.5 million for the same period in 2021, and $32.5 million during the six months ended June 30, 2022, compared to $21.7 million for the same period in 2021.
    • Net loss for the second quarter of 2022 was $176.4 million, or $3.18 per share basic and diluted, compared to a net loss of $166.4 million, or $3.23 per share basic and diluted for the same period in 2021. Net loss for the six months ended June 30, 2022 was $364.8 million, or $6.57 per share basic and diluted, compared to a net loss of $302.1 million, or $5.91 per share basic and diluted for the same period in 2021.

    Conference Call Information  

    There will be a conference call on August 3, 2022 at 4:30 p.m. ET / 1:30 p.m. PT during which company executives will review financial information for the second quarter of 2022 and provide corporate updates.

    Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 313-209-4906 or international +1 877-502-9276, confirmation code: 1791105.

    A replay of the call will be available approximately 2 hours after the event has ended at the same website.

    About Mirati Therapeutics, Inc.

    Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook. 

    Forward Looking Statements

    This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (selective KRASG12C inhibitor), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

    Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov). Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

    Mirati Contacts

    Investor Relations: [email protected]

    Media Relations: [email protected]

    1OPDIVO® (nivolumab) is a registered trademark of Bristol Myers Squibb

    Mirati Therapeutics, Inc.

    Consolidated Balance Sheets

    (in thousands)











    June 30,



    December 31,



    2022



    2021

    Assets







    Current assets







    Cash, cash equivalents and short-term investments

    $         1,181,328



    $        1,491,340

    Other current assets

    21,598



    16,643

    Total current assets

    1,202,926



    1,507,983

    Property and equipment, net

    17,163



    15,824

    Long-term investment

    2,635



    8,218

    Right-of-use asset

    36,823



    37,680

    Other long-term assets

    20,243



    19,049

    Total assets

    $        1,279,790



    $       1,588,754









    Liabilities and Shareholders' Equity







    Current liabilities







    Accounts payable

    $             24,269



    $            35,163

    Accrued liabilities

    94,878



    108,495

    Total current liabilities

    119,147



    143,658

    Lease liability

    45,823



    45,879

    Other liabilities

    2,816



    2,179

    Total liabilities

    167,786



    191,716









    Shareholders' equity

    1,112,004



    1,397,038









    Total liabilities and shareholders' equity

    $        1,279,790



    $       1,588,754

     

    Mirati Therapeutics, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (in thousands) 











    Three Months Ended

    June 30,



    Six Months Ended

    June 30,



    2022



    2021



    2022



    2021



    (unaudited)



    (unaudited)

    Revenue















    License and collaboration revenues

    $           5,362



    $                 —



    $           6,071



    $                 —

    Total revenue

    5,362



    —



    6,071



    —

    Expenses















    Research and development

    128,339



    134,575



    259,315



    238,646

    General and administrative

    54,228



    29,611



    108,179



    57,961

    Total operating expenses

    182,567



    164,186



    367,494



    296,607

    Loss from operations

    (177,205)



    (164,186)



    (361,423)



    (296,607)

    Other income (expense), net

    760



    (2,244)



    (3,408)



    (5,503)

    Net loss

    $      (176,445)



    $      (166,430)



    $      (364,831)



    $      (302,110)

    Unrealized (loss) gain on available-for-sale investments

    (909)



                  

    145



    (5,711)



    (158)

    Comprehensive loss

    $      (177,354)



    $      (166,285)



    $      (370,542)



    $      (302,268)

    Net loss per share, basic and diluted

    $            (3.18)



    $            (3.23)



    $            (6.57)



    $            (5.91)

    Weighted average common shares outstanding, basic and diluted

    55,552



    51,473



    55,511



    51,128

     

    Logo (PRNewsfoto/Mirati Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-updates-301599371.html

    SOURCE Mirati Therapeutics, Inc.

    Get the next $MRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$51.00 → $48.00Neutral → Buy
    Citigroup
    8/9/2023$45.00Neutral → Buy
    B. Riley Securities
    8/9/2023$45.00Overweight
    Piper Sandler
    7/27/2023Sector Underperform
    Scotiabank
    5/25/2023Perform → Outperform
    Oppenheimer
    12/14/2022Hold
    Needham
    12/9/2022$121.00 → $53.00Buy → Neutral
    Citigroup
    12/8/2022$110.00 → $59.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $MRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

      SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ

      1/10/24 8:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

      SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati

      11/2/23 7:30:00 AM ET
      $KURA
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

      Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh

      10/8/23 5:16:00 PM ET
      $BMY
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mirati Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously

      8/10/23 7:25:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00

      8/9/23 8:29:32 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Mirati Therapeutics with a new price target

      Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00

      8/9/23 7:36:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Boxer Capital, Llc returned 6,859,544 shares to the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/25/24 4:32:24 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cherrington Julie M returned 11,252 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:07 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharp Shalini returned 16,222 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:09 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Financials

    Live finance-specific insights

    See more
    • Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

      Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum, M.D., Ph.D., President and Founder, to assume role of interim CEO during search for permanent CEO Company will announce financial results for the second quarter 2023 along with recent corporate updates during a conference call at 5:30 p.m. ET / 2:30 p.m. PT SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASD

      8/8/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

      SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 6674271. A replay of the call will be available approximately 2 hours after

      7/25/23 4:30:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

      SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In add

      5/9/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mirati Therapeutics Inc.

      SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 4:21:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 2:51:56 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 9:13:21 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KRAZATI issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/14/22 7:40:10 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/12/22 6:09:02 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy

      12/12/22 4:56:01 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Mirati Therapeutics Inc.

      15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)

      2/2/24 4:05:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:14 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:09 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

      SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer." Dr. Gallagher has over 30 years of strategic, commercial, business development and drug dev

      6/23/23 4:00:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

      Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pr

      11/8/22 4:05:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

      - Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine. Prior to Medikine, he was Executive Vice President a

      10/4/22 4:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care